IL6 and Huntington disease: Previous studies have shown that both ACEIs and ARBs may decrease some inflammation markers, including IL-6 and CRP18,19,29, but this issue remains controversial30; moreover, there was no information whether these drugs may have an additive or synergistic effect in HD patients.